On August 5, Hong Kong-listed innovative pharmaceutical company Jiahe Biologics (06998.HK) announced that the group entered into a licensing agreement and equity agreement with TRC2004, Inc. on August 2. Pursuant to the License Agreement, the Group has agreed, among other things, to grant TRC2004 an exclusive global license (excluding Mainland China, Hong Kong, Macau and Taiwan) to develop, use, manufacture, commercialize and otherwise exploit GB261.

According to the terms of the license agreement and equity agreement, as consideration for the license, the Group will receive a considerable amount of equity in TRC2004, an down payment of tens of millions of US dollars, milestone payments of up to US$443 million, and a single-digit to double-digit share of net sales. percentage tiered royalties.

CD3/CD20 inhibitor potential stocks. GB261 is a new type of differentiated CD20/CD3 bispecific T cell engager (TCE) and the first T cell engager (T-cell Engager) that binds to CD3 with low affinity and maintains Fc function (ADCC and CDC). GB261 significantly inhibits the growth of rituximab-resistant cancer cells through in vitro assays and in vivo models. It activates T cells and has lower cytokine release than similar products. Therefore, GB261 is a very potential bispecific therapeutic antibody for B-cell malignancies. With significant competitive advantages over other CD3/CD20 inhibitors, GB261 is expected to become a better and safer T cell engager treatment drug.

Jiahe Biotech has previously successfully completed Phase I/II multi-center studies in B-NHL (DLBCL and FL) in China and Australia. The results showed very superior safety and effectiveness. For example, GB261 has been shown to significantly reduce cytokine release (CRS) compared to other similar compounds. The properties of GB261 make it a very promising B-cell depleting agent with indication potential beyond oncology and into a variety of immunological and autoimmune indications where there is substantial unmet medical need in patients. The collaboration with TRC2004 will mainly focus on exploring the potential of GB261 in autoimmune diseases.

TRC2004 is a company co-founded by Two River Fund and Third Rock Ventures Fund, both experienced company founders, each focused on optimizing disruptive treatment technologies for patients. TwoRiver founded several cell therapy companies, including KitePharma, developer of the CD19 CAR-T therapy Yescarta® (acquired by Gilead Sciences). ThirdRock Ventures is a leading healthcare venture capital fund that has raised $3.8 billion since its inception, driving investments in more than 60 portfolio companies that have brought to market numerous therapeutic modalities and indications. product. GB261 is one of the core assets of Jiahe Biotechnology. This time it has found a high-quality overseas development partner. We look forward to the development of GB261 bearing more innovative fruits.

According to incomplete statistics, in the first half of 2024, Chinese local pharmaceutical companies concluded a total of 60 cross-border BD transactions, a significant increase compared with the same period in 2023. Among them, the number of cross-border license-out transactions reached 43, which is half of the number in the whole year of 2023. In the second half of 2024, the licensing-out craze for domestic innovative drugs will continue. Recently, many domestic innovative pharmaceutical companies have successively announced news of external licensing cooperation.

On August 1, Immune Onco and InstilBio announced an agreement. According to the agreement, Instil will obtain the development and commercialization rights of Immune Onco's proprietary PD-L1xVEGF bispecific antibody IMM2510 and the next-generation CTLA-4 antibody IMM27M outside Greater China, while Immune Onco will retain the rights in Greater China. development and commercialization rights in the region, including Taiwan, Macau and Hong Kong. The transaction includes an upfront payment of US$50 million and potential near-term payments, and is expected to receive a total of more than US$2 billion in milestone payments when certain development, regulatory and commercial milestones are achieved, as well as based on global (excluding Greater China) net sales. Sales commissions ranging from single digits to low double digits.

On July 31, Biocytogen announced that it had reached an option and licensing agreement with IDEAYABiosciences, a precision oncology company dedicated to discovering and developing targeted therapeutic drugs, for a potentially first-of-its-kind B7H3/PTK7BsADC project. Under the terms of the agreement, Biocyto will receive an upfront payment and, if IDEAYA exercises the option, Biocyto is entitled to receive option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and single-digit net sales shares . The potential transaction totals $406.5 million, including $100 million in clinical development and regulatory milestone payments.

On July 17, Huolian Technology announced that it had signed an external licensing agreement with SK Biopharmaceuticals, a South Korean biotechnology company. Under the agreement, Hualian Technology has granted SK Biopharmaceuticals exclusive rights to conduct clinical research, development, production and commercialization of FL-091 radiopharmaceuticals worldwide, targeting neurotensin receptor type 1 (NTSR1)-positive cancers. . The total transaction value is US$571.5 million, including down payment, R&D and commercial milestone payments, and royalties are not included. Under the terms of the agreement, SK Biopharmaceuticals will license the introduction of FL-091, a radiopharmaceutical conjugate (RDC) project targeting NTSR1, and its candidate compounds, and develop them into an innovative anti-tumor drug.

https://news.yaozh.com/archive/43939.html